Education and Training
- Fellow in Endocrinology, Medicine, Vanderbilt University, 2006 - 2009
- Resident, Medicine, Virginia Commonwealth University, 2003 - 2006
- M.D., Dartmouth College, 2003
Cox, C, Bosley, M, Southerland, LB, Ahmadi, S, Perkins, J, Roman, S, Sosa, JA, and Carneiro-Pla, D. "Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?." Surgery 163, no. 1 (January 2018): 75-80.
Ruel, E, Thomas, S, Perkins, JM, Roman, SA, and Sosa, JA. "The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer." Annals of Surgical Oncology 24, no. 7 (July 2017): 1935-1942.
Perkins, JM. "Considerations in thyrotropin-stimulating hormone suppression in individuals with differentiated thyroid cancer." In Management of Differentiated Thyroid Cancer, 223-232. June 24, 2017.
Shariff, AI, Gratian, L, and Perkins, J. "A rare presentation of TSH secreting pituitary macroadenoma with coexisting primary hypothyroidism from Hashimoto’s thyroiditis." In The Art of Neuroendocrinology: A Case-Based Approach to Medical Decision-Making, 35-44. January 1, 2017.
Joy, NG, Perkins, JM, Mikeladze, M, Younk, L, Tate, DB, and Davis, SN. "Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans." Journal of diabetes and its complications 30, no. 7 (September 2016): 1275-1281.
Ruel, E, Thomas, S, Dinan, MA, Perkins, JM, Roman, SA, and Sosa, JA. "Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer." Endocrine 52, no. 3 (June 2016): 579-586.
Perkins, JM, Joy, NG, Tate, DB, and Davis, SN. "Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans." American Journal of Physiology. Endocrinology and Metabolism 309, no. 2 (July 2015): E168-E176.
Goffredo, P, Thomas, SM, Dinan, MA, Perkins, JM, Roman, SA, and Sosa, JA. "Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: use and misuse." Jama Internal Medicine 175, no. 4 (April 2015): 638-640.
Ruel, E, Thomas, S, Dinan, M, Perkins, JM, Roman, SA, and Sosa, JA. "Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer." The Journal of Clinical Endocrinology and Metabolism 100, no. 4 (April 2015): 1529-1536.
Bohinc, BN, and Perkins, JM. "Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer." Curr Opin Oncol 26, no. 1 (January 2014): 31-35. (Review)